GLP-1 Receptor Agonist and SGLT2 Inhibitor Prescribing in People With Type 1 Diabetes

Piaopiao Li; Zhiyan Li; Elizabeth Staton; Guillermo E Umpierrez; Georgia Davis; Hui Shao; Francisco J Pasquel

doi:10.1001/jama.2024.18581

GLP-1 Receptor Agonist and SGLT2 Inhibitor Prescribing in People With Type 1 Diabetes

JAMA. 2024 Nov 19;332(19):1667-1669. doi: 10.1001/jama.2024.18581.

Authors

Piaopiao Li^{1

2}, Zhiyan Li¹, Elizabeth Staton³, Guillermo E Umpierrez⁴, Georgia Davis⁴, Hui Shao^{1

5}, Francisco J Pasquel^{1

4}

Affiliations

¹ Hubert Department of Global Health, Emory University Rollins School of Public Health, Atlanta, Georgia.
² Department of Pharmaceutical Outcomes and Policy, University of Florida College of Pharmacy, Gainesville.
³ Department of Health Policy and Management, Emory University Rollins School of Public Health, Atlanta, Georgia.
⁴ Division of Endocrinology, Emory University School of Medicine, Atlanta, Georgia.
⁵ Department of Family and Preventive Medicine, Emory University School of Medicine, Atlanta, Georgia.

PMID: 39441612
PMCID: PMC11500011 (available on 2025-04-23)
DOI: 10.1001/jama.2024.18581

No abstract available

Plain language summary

This pooled cross-sectional study explores prescribing rates for glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors among US patients with type 1 diabetes.